ADAMA LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.98 CNY | +1.18% |
|
-4.17% | -13.83% |
| Apr. 15 | ADAMA Ltd. Launches Maganic® | CI |
| Apr. 09 | ADAMA Ltd Launches New Multi-Crop, Broad Spectrum Fungicide Maxentis® for Improved Disease Control and Increased Yield | CI |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.54 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 92.44 times its estimated earnings per share for the ongoing year.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Agricultural Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.83% | 1.82B | B- | ||
| -7.16% | 3.24B | C- | ||
| -25.13% | 2.01B | C+ | ||
| +1.38% | 1.78B | - | ||
| -10.31% | 1.53B | - | ||
| -1.72% | 1.22B | B | ||
| -7.75% | 1.06B | - | - | |
| -24.98% | 993M | - | ||
| -19.83% | 850M | - | - | |
| -5.78% | 763M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 000553 Stock
- Ratings ADAMA Ltd.
